RecruitingPhase 3NCT07326813

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis


Sponsor

InventisBio Co., Ltd

Enrollment

477 participants

Start Date

Jan 12, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986165 Tablet, a drug called D-2570 Tablet, and others for people with plaque psoriasis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGD-2570 Tablet

D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain

DRUGBMS-986165 Tablet

BMS-986165 is a novel inhibitor targeting TYK2

DRUGPlacebo

A placebo refers to a tablet that has no therapeutic effect on medication


Locations(1)

Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07326813


Related Trials